New trial aims to halt spread of aggressive prostate cancer with precision radiation

NCT ID NCT07426094

Recruiting now Disease control Sponsor: Affidea Nu-med Center of Oncological DIagnostics and Therapy Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 22, 2026 · Updated 3 times

Summary

This clinical trial is for men with prostate cancer that has spread to nearby pelvic lymph nodes but not further. It compares two radiation strategies: one that gives a higher dose to the prostate only, and another that boosts both the prostate and the affected lymph nodes. All participants receive whole-pelvis radiation and hormone therapy. The goal is to see which approach better prevents the cancer from spreading to distant parts of the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ultrahypofractionated whole-pelvis radiotherapy with optional prostate boost (via brachytherapy or SBRT) and nodal boost
What this could lead to: If successful, this trial could show the best way to intensify radiotherapy for node-positive prostate cancer, potentially improving metastasis-free survival and guiding future treatment standards.
What could go wrong: This is an early-to-mid-stage trial (phase II/III) with 1600 participants, and results may not confirm superiority of one approach. Long-term androgen deprivation therapy is required, and side effects from intensified radiation could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRACHYTHERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma Neoplasm Metastasis prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRACHYTHERAPY DOSE ESCALATION: SOLID TUMORS PROSTATE CANCER REGIONALLY ADVANCED PROSTATE CANCER STEREOTACTIC BODY RADIATION THERAPY (SBRT)

Contacts and locations

Locations

Affidea Nu-Med, Center of Oncological Diagnostics and Therapy
RECRUITING

Zamość, Lublin Voivodeship, 22-400, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.